Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics (NASDAQ:VYGR), a biotechnology company focused on neurological diseases, has announced its participation in six major investor conferences in September 2025. The company will present at the Citi Biopharma, Wells Fargo Healthcare, Cantor Global Healthcare, Morgan Stanley Global Healthcare, Baird Global Healthcare, and H.C. Wainwright Global Investment conferences.
During these presentations, Voyager plans to discuss its non-viral delivery platform and novel receptor-binding molecules for transporting neurotherapeutics across the blood-brain barrier. Webcasts for the Citi and Baird presentations will be available on the company's investor relations website for at least 30 days.
Voyager Therapeutics (NASDAQ:VYGR), azienda biotecnologica specializzata in patologie neurologiche, ha annunciato la partecipazione a sei importanti conferenze per investitori previste per settembre 2025. L'azienda interverrà ai convegni Citi Biopharma, Wells Fargo Healthcare, Cantor Global Healthcare, Morgan Stanley Global Healthcare, Baird Global Healthcare e H.C. Wainwright Global Investment.
Nel corso delle presentazioni, Voyager illustrerà la sua piattaforma di somministrazione non virale e nuove molecole leganti recettori progettate per veicolare terapie neurologiche attraverso la barriera ematoencefalica. Le webcast degli interventi a Citi e Baird saranno disponibili sul sito investor relations della società per almeno 30 giorni.
Voyager Therapeutics (NASDAQ:VYGR), una biotecnológica centrada en enfermedades neurológicas, ha anunciado su participación en seis importantes conferencias para inversores en septiembre de 2025. La compañía presentará en Citi Biopharma, Wells Fargo Healthcare, Cantor Global Healthcare, Morgan Stanley Global Healthcare, Baird Global Healthcare y H.C. Wainwright Global Investment.
Durante estas presentaciones, Voyager expondrá su plataforma de administración no viral y nuevas moléculas ligantes de receptores diseñadas para transportar neuroterapéuticos a través de la barrera hematoencefálica. Las retransmisiones web de las presentaciones en Citi y Baird estarán disponibles en la web de relaciones con inversores de la compañía durante al menos 30 días.
Voyager Therapeutics (NASDAQ:VYGR), 신경계 질환에 주력하는 바이오테크 기업이 2025년 9월에 열리는 주요 투자자 콘퍼런스 6곳에 참가한다고 발표했습니다. 회사는 Citi Biopharma, Wells Fargo Healthcare, Cantor Global Healthcare, Morgan Stanley Global Healthcare, Baird Global Healthcare, H.C. Wainwright Global Investment 콘퍼런스에서 발표할 예정입니다.
발표에서 Voyager는 비바이러스성 전달 플랫폼과 혈뇌장벽을 통해 신경치료제를 운반하기 위한 새로운 수용체 결합 분자들을 소개할 계획입니다. Citi 및 Baird 발표의 웹캐스트는 회사의 투자자관계 웹사이트에서 최소 30일간 시청할 수 있습니다.
Voyager Therapeutics (NASDAQ:VYGR), une société de biotechnologie spécialisée dans les maladies neurologiques, a annoncé sa participation à six grandes conférences investisseurs en septembre 2025. La société présentera aux conférences Citi Biopharma, Wells Fargo Healthcare, Cantor Global Healthcare, Morgan Stanley Global Healthcare, Baird Global Healthcare et H.C. Wainwright Global Investment.
Lors de ces interventions, Voyager exposera sa plateforme d'administration non virale et de nouvelles molécules liant des récepteurs, conçues pour acheminer des neurothérapeutiques à travers la barrière hémato-encéphalique. Les webcasts des présentations Citi et Baird seront disponibles sur le site relations investisseurs de la société pendant au moins 30 jours.
Voyager Therapeutics (NASDAQ:VYGR), ein Biotechnologieunternehmen mit Fokus auf neurologische Erkrankungen, hat seine Teilnahme an sechs wichtigen Investorenkonferenzen im September 2025 bekanntgegeben. Das Unternehmen wird auf den Konferenzen Citi Biopharma, Wells Fargo Healthcare, Cantor Global Healthcare, Morgan Stanley Global Healthcare, Baird Global Healthcare und H.C. Wainwright Global Investment präsentieren.
Bei diesen Präsentationen will Voyager seine nicht-virale Delivering-Plattform sowie neuartige rezeptorbindende Moleküle vorstellen, die Neurotherapeutika über die Blut-Hirn-Schranke transportieren sollen. Webcasts der Präsentationen bei Citi und Baird werden auf der Investor-Relations-Website des Unternehmens für mindestens 30 Tage verfügbar sein.
- None.
- None.
LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:
- Citi's 2025 Biopharma Back to School Conference: Fireside chat at 4:00 p.m. ET on Tuesday, September 2, 2025, in Boston, MA, during which the company plans to highlight preclinical data supporting its non-viral delivery platform leveraging novel receptor-binding molecules to transport multiple modalities of neurotherapeutics across the blood-brain barrier.
- 2025 Wells Fargo Healthcare Conference: Fireside chat at 4:30 p.m. ET on Wednesday, September 3, 2025, in Boston, MA.
- Cantor Global Healthcare Conference 2025: Fireside chat at 1:35 p.m. ET on Thursday, September 4, 2025, in New York, NY.
- Morgan Stanley 23rd Annual Global Healthcare Conference: Available for one-on-one meetings on Monday, September 8, 2025, in New York, NY.
- Baird 2025 Global Healthcare Conference: Fireside chat at 9:05 a.m. ET on Tuesday, September 9, 2025, in New York, NY.
- H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat at 2:30 p.m. ET on Tuesday, September 9, 2025, in New York, NY.
Webcasts of the Citi and Baird fireside chats will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of these two webcasts will be archived on the company’s website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Sarah McCabe, smccabe@jpa.com
Media: Adam Silverstein, adam@scientpr.com
FAQ
When is Voyager Therapeutics (VYGR) presenting at the Citi Biopharma Conference 2025?
What technology will Voyager Therapeutics discuss at the conferences?
How can investors access Voyager's conference presentations?
Which investor conferences will Voyager Therapeutics attend in September 2025?
